Targeting the tumor stroma with Peroxisome Proliferator Activated Receptor (PPAR) agonists

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 7, 2009, Pages 816-821

  Bundscherer, Annika ^a   Reichle, Albrecht ^a   Hafner, Christian ^a   Meyer, Stefanie ^a   Vogt, Thomas ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Biomodulation; Cancer; Metronome chemotherapy; PPAR; Stroma; Targeting; Thiazolidinedione

Indexed keywords

CAPECITABINE; CIGLITAZONE; CYCLOOXYGENASE 2 INHIBITOR; GLITAZONE DERIVATIVE; HORMONE RECEPTOR STIMULATING AGENT; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; NETOGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; RETINOIC ACID RECEPTOR AGONIST; RETINOID X RECEPTOR AGONIST; RIVOGLITAZONE; ROSIGLITAZONE; THROMBOSPONDIN 1; TROGLITAZONE; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ATHEROSCLEROSIS; BRAIN INFARCTION; CANCER INVASION; CANCER RESEARCH; CANCER RESISTANCE; CLEAR CELL CARCINOMA; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; IMMUNOMODULATION; KIDNEY CARCINOMA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MELANOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PHARMACODYNAMICS; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; STROMA; TOXIC HEPATITIS; TUMOR ESCAPE; TUMOR IMMUNITY; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; STROMAL CELLS;

EID: 73449092810     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152009789056912     Document Type: Review

References (68)

1. Reichle, A.;Vogt, T. Systems biology: a therapeutic target for tumor therapy. Cancer Microenviron., 2008, 1(1), 159-170.
2. Hafner, C.; Reichle, A.;Vogt, T. New indications for established drugs: combined tumor-stroma-targeted cancer therapy with PPARgamma agonists, COX-2 inhibitors, mTOR antagonists and metronomic chemotherapy. Curr. Cancer Drug Targets, 2005, 5(6), 393-419.
3. Hofmeister, V.; Schrama, D.;Becker, J.C. Anti-cancer therapies targeting the tumor stroma. Cancer Immunol. Immunother., 2008, 57(1), 1-17.
4. Konstantinopoulos, P.A.; Vandoros, G.P.; Sotiropoulou-Bonikou, G.; Kominea, A.;Papavassiliou, A.G. NF-kappaB/PPARgamma and/or AP-1/PPARgamma 'on/off' switches and induction of CBP in colon adenocarcinomas: correlation with COX-2 expression. Int. J. Colorectal Dis., 2006.
5. Boehm, T.; Folkman, J.; Browder, T.;O'Reilly, M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature, 1997, 390(6658), 404-407.
6. Guba, M.; von Breitenbuch, P.; Steinbauer, M.; Koehl, G.; Flegel, S.; Hornung, M.; Bruns, C.J.; Zuelke, C.; Farkas, S.; Anthuber, M.; Jauch, K.W.;Geissler, E.K. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med., 2002, 8(2), 128-135.
7. Panigrahy, D.; Singer, S.; Shen, L.Q.; Butterfield, C.E.; Freedman, D.A.; Chen, E.J.; Moses, M.A.; Kilroy, S.; Duensing, S.; Fletcher, C.; Fletcher, J.A.; Hlatky, L.; Hahnfeldt, P.; Folkman, J.;Kaipainen, A. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J. Clin. Invest., 2002, 110(7), 923-932.
8. Carmeliet, P.;Jain, R.K. Angiogenesis in cancer and other diseases. Nature, 2000, 407(6801), 249-257.
9. de Castro Junior, G.; Puglisi, F.; de Azambuja, E.; El Saghir, N.S.;Awada, A. Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm). Crit. Rev. Oncol. Hematol., 2006, 59(1), 40-50.
10. Cao, Y. Antiangiogenic cancer therapy. Semin. Cancer Biol., 2004, 14(2), 139-145.
11. Patan, S.; Munn, L.L.;Jain, R.K. Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: a novel mechanism of tumor angiogenesis. Microvasc. Res., 1996, 51(2), 260-272.
12. Hillen, F.;Griffioen, A.W. Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev., 2007, 26(3-4), 489-502.
13. Folberg, R.;Maniotis, A.J. Vasculogenic mimicry. APMIS, 2004, 112(7-8), 508-525.
14. Baluk, P.; Morikawa, S.; Haskell, A.; Mancuso, M.; McDonald, D.M. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am. J. Pathol., 2003, 163(5), 1801-1815.
15. di Tomaso, E.; Capen, D.; Haskell, A.; Hart, J.; Logie, J.J.; Jain, R.K.; McDonald, D.M.; Jones, R.;Munn, L.L. Mosaic tumor vessels: cellular basis and ultrastructure of focal regions lacking endothelial cell markers. Cancer Res., 2005, 65(13), 5740-5749.
16. Hashizume, H.; Baluk, P.; Morikawa, S.; McLean, J.W.; Thurston, G.; Roberge, S.; Jain, R.K.;McDonald, D.M. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol., 2000, 156(4), 1363-1380.
17. Sertznig, P.; Seifert, M.; Tilgen, W.;Reichrath, J. Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer. J. Cell Physiol., 2007, 212(1), 1-12.
18. Xin, X.; Yang, S.; Kowalski, J.;Gerritsen, M.E. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J. Biol. Chem., 1999, 274(13), 9116-9121.
19. Goetze, S.; Bungenstock, A.; Czupalla, C.; Eilers, F.; Stawowy, P.; Kintscher, U.; Spencer-Hansch, C.; Graf, K.; Nurnberg, B.; Law, R.E.; Fleck, E.;Grafe, M. Leptin induces endothelial cell migration through Akt, which is inhibited by PPARgamma-ligands. Hypertension, 2002, 40(5), 748-754.
20. Murata, T.; Hata, Y.; Ishibashi, T.; Kim, S.; Hsueh, W.A.; Law, R.E.;Hinton, D.R. Response of experimental retinal neovascularization to thiazolidinediones. Arch. Ophthalmol., 2001, 119(5), 709-717.
21. Bishop-Bailey, D.;Hla, T. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2. J. Biol. Chem., 1999, 274(24), 17042-17048.
22. Tsuzuki, T.; Kawakami, Y. Tumor angiogenesis suppression by {alpha}-eleostearic acid, a linolenic acid isomer with a conjugated triene system, via peroxisome proliferator-activated receptor {gamma}. Carcinogenesis, 2008, 29(4), 797-806.
23. Zhang, J.; Fu, M.; Zhao, L.;Chen, Y.E. 15-Deoxy-prostaglandin J(2) inhibits PDGF-A and -B chain expression in human vascular endothelial cells independent of PPAR gamma. Biochem. Biophys. Res. Commun., 2002, 298(1), 128-132.
24. Artwohl, M.; Furnsinn, C.; Waldhausl, W.; Holzenbein, T.; Rainer, G.; Freudenthaler, A.; Roden, M.;Baumgartner-Parzer, S.M. Thiazolidinediones inhibit proliferation of microvascular and macrovascular cells by a PPARgamma-independent mechanism. Diabetologia, 2005, 48(3), 586-594.
25. Chu, K.; Lee, S.T.; Koo, J.S.; Jung, K.H.; Kim, E.H.; Sinn, D.I.; Kim, J.M.; Ko, S.Y.; Kim, S.J.; Song, E.C.; Kim, M.;Roh, J.K. Peroxisome proliferator-activated receptor-gamma-agonist, rosiglitazone, promotes angiogenesis after focal cerebral ischemia. Brain Res., 2006, 1093(1), 208-218.
26. Mannucci, E.; Monami, M.; Lamanna, C.; Gensini, G.F.; Marchionni, N. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes. Metab., 2008, 10(12), 1221-38.
27. Dahabreh, I.J. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone. Clin. Trials, 2008, 5(2), 116-120.
28. Margeli, A.; Kouraklis, G.;Theocharis, S. Peroxisome proliferator activated receptor-gamma (PPARgamma) ligands and angiogenesis. Angiogenesis, 2003, 6(3), 165-169.
29. Reichle, A.; Bross, K.; Vogt, T.; Bataille, F.; Wild, P.; Berand, A.; Krause, S.W.;Andreesen, R. Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma. Cancer, 2004, 101(10), 2247-2256.
30. Reichle, A.; Grassinger, J.; Bross, K.; Wilke, J.; Suedhoff, T.; Walter, B.; Wieland, W.; Berand, A.;Andreesen, R. C-reactive protein in patients with metastatic clear cell renal carcinoma: an important biomarker for tumor-associated inflammation. Biomarker Insights, 2006, I, 87-98 online journal.
31. Reichle, A.; Vogt, T.; Coras, B.; Terheyden, P.; Neuber, K.; Trefzer, U.; Schultz, E.; Berand, A.; Brocker, E.B.; Landthaler, M.;Andreesen, R. Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma: a randomized phase II trial. Melanoma Res., 2007, 17(6), 360-364.
32. Reichle, A.; Vogt, T.; Kunz-Schughart, L.; Bretschneider, T.; Bachthaler, M.; Bross, K.; Freund, S.; Andreesen, R. Antiinflammatory and angiostatic therapy in chemorefractory multisystem Langerhans' cell histiocytosis of adults. Br. J. Haematol., 2005, 128(5), 730-732.
33. Reichle, A.; Walpinski, S.; Vogelhuber, M.; Wiedmann, K.; Berand, A.; Endlicher, E.; Klebl, F.; Schölmerich, J.; Andreesen, R.;Wiest, R. Targeted anti-inflammatroy and angiostatic therapy in pretreated patients with advanced hepatocellular carcinoma. J. Clin. Oncol., ASCO, 2008, 26(May 20 Suppl.), abstract 15560.
34. Reichle, A.; Walter, B.; Berand, A.; Vogelhuber, M.; Bross, K.; Wilke, J.; Wieland, W.; Andreesen, R.; Rogenhofer, S. Induction of complete remission in metastatic hormone-refractory prostate cancer: A combined anti-inflammatory therapy approch. J. Clin. Oncol., ASCO, 2007, 25(18S (June 20 Suppl.) Abstract no 15636).
35. Huang, H.; Campbell, S.C.; Bedford, D.F.; Nelius, T.; Veliceasa, D.; Shroff, E.H.; Henkin, J.; Schneider, A.; Bouck, N.;Volpert, O.V. Peroxisome proliferator-activated receptor gamma ligands improve the antitumor efficacy of thrombospondin peptide ABT510. Mol. Cancer Res., 2004, 2(10), 541-550.
36. Keshamouni, V.G.; Arenberg, D.A.; Reddy, R.C.; Newstead, M.J.; Anthwal, S.; Standiford, T.J. PPARgamma activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer. Neoplasia, 2005, 7(3), 294-301.
37. Tanaka, T.; Fukunaga, Y.; Itoh, H.; Doi, K.; Yamashita, J.; Chun, T.H.; Inoue, M.; Masatsugu, K.; Saito, T.; Sawada, N.; Sakaguchi, S.; Arai, H.; Nakao, K. Therapeutic potential of thiazolidinediones in activation of peroxisome proliferator-activated receptor gamma for monocyte recruitment and endothelial regeneration. Eur. J. Pharmacol., 2005, 508(1-3), 255-265.
38. Wang, C.H.; Ciliberti, N.; Li, S.H.; Szmitko, P.E.; Weisel, R.D.; Fedak, P.W.; Al-Omran, M.; Cherng, W.J.; Li, R.K.; Stanford, W.L.; Verma, S. Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy. Circulation, 2004, 109(11), 1392-1400.
39. Yamakawa, K.; Hosoi, M.; Koyama, H.; Tanaka, S.; Fukumoto, S.; Morii, H.;Nishizawa, Y. Peroxisome proliferator-activated receptor-gamma agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells. Biochem. Biophys. Res. Commun., 2000, 271(3), 571-574.
40. Gensch, C.; Clever, Y.P.; Werner, C.; Hanhoun, M.; Bohm, M.; Laufs, U. The PPARgamma agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells. Atherosclerosis, 2007, 192(1), 67-74.
41. Pistrosch, F.; Herbrig, K.; Oelschlaegel, U.; Richter, S.; Passauer, J.; Fischer, S.;Gross, P. PPAR gamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells. Atherosclerosis, 2005, 183(1), 163-167.
42. Wang, C.H.; Ting, M.K.; Verma, S.; Kuo, L.T.; Yang, N.I.; Hsieh, I.C.; Wang, S.Y.; Hung, A.; Cherng, W.J. Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus. Am. Heart J., 2006, 152(6), 1051 e1051-1058.
43. Redondo, S.; Hristov, M.; Gumbel, D.; Tejerina, T.;Weber, C. Biphasic effect of pioglitazone on isolated human endothelial progenitor cells: involvement of peroxisome proliferator-activated receptor-gamma and transforming growth factor-beta1. Thromb Haemost., 2007, 97(6), 979-987.
44. Panigrahy, D.; Huang, S.; Kieran, M.W.; Kaipainen, A. PPARgamma as a therapeutic target for tumor angiogenesis and metastasis. Cancer Biol. Ther., 2005, 4(7), 687-693.
45. Ferruzzi, P.; Ceni, E.; Tarocchi, M.; Grappone, C.; Milani, S.; Galli, A.; Fiorelli, G.; Serio, M.; Mannelli, M. Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R. J. Clin. Endocrinol. Metab., 2005, 90(3), 1332-1339.
46. Galli, A.; Ceni, E.; Crabb, D.W.; Mello, T.; Salzano, R.; Grappone, C.; Milani, S.; Surrenti, E.; Surrenti, C.; Casini, A. Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms. Gut, 2004, 53(11), 1688-1697.
47. Grommes, C.; Landreth, G.E.; Sastre, M.; Beck, M.; Feinstein, D.L.; Jacobs, A.H.; Schlegel, U.; Heneka, M.T. Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment. Mol. Pharmacol., 2006, 70(5), 1524-1533.
48. Shen, D.; Deng, C.;Zhang, M. Peroxisome proliferator-activated receptor gamma agonists inhibit the proliferation and invasion of human colon cancer cells. Postgrad. Med. J., 2007, 83(980), 414-419.
49. Magenta, G.; Borenstein, X.; Rolando, R.; Jasnis, M.A. Rosiglitazone inhibits metastasis development of a murine mammary tumor cell line LMM3. BMC Cancer, 2008, 8, 47.
50. Coras, R.; Holsken, A.; Seufert, S.; Hauke, J.; Eyupoglu, I.Y.; Reichel, M.; Trankle, C.; Siebzehnrubl, F.A.; Buslei, R.; Blumcke, I.;Hahnen, E. The peroxisome proliferator-activated receptor-gamma agonist troglitazone inhibits transforming growth factor-beta-mediated glioma cell migration and brain invasion. Mol. Cancer Ther., 2007, 6(6), 1745-1754.
51. Szanto, A.;Nagy, L. Retinoids potentiate peroxisome proliferator- activated receptor gamma action in differentiation, gene expression, and lipid metabolic processes in developing myeloid cells. Mol. Pharmacol., 2005, 67(6), 1935-1943.
52. Mantovani, A.; Allavena, P.; Sica, A.; Balkwill, F. Cancer-related inflammation. Nature, 2008, 454(7203), 436-444.
53. Van Ginderachter, J.A.; Meerschaut, S.; Liu, Y.; Brys, L.; De Groeve, K.; Hassanzadeh Ghassabeh, G.; Raes, G.; De Baetselier, P. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer. Blood, 2006, 108(2), 525-535.
54. Szatmari, I.; Gogolak, P.; Im, J.S.; Dezso, B.; Rajnavolgyi, E.;Nagy, L. Activation of PPARgamma specifies a dendritic cell subtype capable of enhanced induction of iNKT cell expansion. Immunity, 2004, 21(1), 95-106.
55. Hau, P.; Kunz-Schughart, L.; Bogdahn, U.; Baumgart, U.; Hirschmann, B.; Weimann, E.; Muhleisen, H.; Ruemmele, P.; Steinbrecher, A.; Reichle, A. Low-dose chemotherapy in combination with COX-2 inhibitors and PPARgamma agonists in recurrent high-grade gliomas - a phase II study. Oncology, 2007, 73(1-2), 21-25.
56. Wan, Y.; Chong, L.W.; Evans, R.M. PPARgamma regulates osteoclastogenesis in mice. Nat. Med., 2007, 13(12), 1496-1503.
57. Kerbel, R.S.; Yu, J.; Tran, J.; Man, S.; Viloria-Petit, A.; Klement, G.; Coomber, B.L.;Rak, J. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev., 2001, 20(1-2), 79-86.
58. Vogt, T.; Hafner, C.; Bross, K.; Bataille, F.; Jauch, K.W.; Berand, A.; Landthaler, M.; Andreesen, R.;Reichle, A. Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer, 2003, 98(10), 2251-2256.
59. Stadlmann, S.; Gueth, U.; Wight, E.; Kunz-Schughart, L.; Hartmann, A.;Singer, G. Expression of peroxisome proliferator activated receptor-gamma and cyclooxygenase-2 in primary and recurrent ovarian carcinoma. J. Clin. Pathol., 2006, 60(3), 307-310.
60. Lonnroth, C.; Andersson, M.; Arvidsson, A.; Nordgren, S.; Brevinge, H.; Lagerstedt, K.; Lundholm, K. Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer. Cancer Immun., 2008, 8, 5.
61. Antonakopoulos, N.; Karamanolis, D.G. The role of NSAIDs in colon cancer prevention. Hepatogastroenterology, 2007, 54(78), 1694-1700.
62. Asou, H.; Verbeek, W.; Williamson, E.; Elstner, E.; Kubota, T.; Kamada, N.;Koeffler, H.P. Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor gamma, and retinoids. Int. J. Oncol., 1999, 15(5), 1027-1031.
63. Crowe, D.L.;Chandraratna, R.A. A retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands. Breast Cancer Res., 2004, 6(5), R546-555.
64. Hirase, N.; Yanase, T.; Mu, Y.; Muta, K.; Umemura, T.; Takayanagi, R.;Nawata, H. Thiazolidinedione induces apoptosis and monocytic differentiation in the promyelocytic leukemia cell line HL60. Oncology, 1999, 57 (Suppl 2), 17-26.
65. Liu, H.; Zang, C.; Fenner, M.H.; Possinger, K.;Elstner, E. PPARgamma ligands and ATRA inhibit the invasion of human breast cancer cells in vitro. Breast Cancer Res. Treat., 2003, 79(1), 63-74.
66. Yamazaki, K.; Shimizu, M.; Okuno, M.; Matsushima-Nishiwaki, R.; Kanemura, N.; Araki, H.; Tsurumi, H.; Kojima, S.; Weinstein, I.B.;Moriwaki, H. Synergistic effects of RXR alpha and PPAR gamma ligands to inhibit growth in human colon cancer cells - phosphorylated RXR alpha is a critical target for colon cancer management. Gut, 2007, 56(11), 1557-1563.
67. McCarty, M.F.; Barroso-Aranda, J.;Contreras, F. PPAR gamma agonists can be expected to potentiate the efficacy of metronomic chemotherapy through CD36 up-regulation. Med. Hypotheses, 2008, 70(2), 419-423.
68. Coras, B.; Hafner, C.; Reichle, A.; Hohenleutner, U.; Szeimies, R.M.; Landthaler, M.;Vogt, T. Antiangiogenic therapy with pioglitazone, rofecoxib, and trofosfamide in a patient with endemic kaposi sarcoma. Arch. Dermatol., 2004, 140(12), 1504-1507.